Recently, Yisheng Bio became the first company to be stopped by IPO. This company mainly engages in the research, development, production and sales of molecular, protein and cell biological reagent , and is an upstream raw material provider in the IVD (in vitro diagnostic) detection industry. Although Yisheng Biology has been established for 8 years, it was mediocre in the five years before the outbreak. Unexpectedly, the performance of the epidemic was ushered in an outbreak.
I don’t know when it started, for us, the nucleic acids that make a living have become the money tree for these companies, and we also want to make another profit by taking advantage of the "Flying Pig" momentum.
Therefore, after the "nucleon gene" incident, , Shanghai Stock Exchange, and Shenzhen Stock Exchange both stated that "the listing applications for nucleic acid testing, will be adhered to strict review." Yisheng Bio's IPO plan was also stranded.
The number of medical testing companies registered in the past three years has exceeded 10,000, and many related companies want to take advantage of the trend to IPO directly. Five nucleic acid companies have passed the IPO this year. Hua Xi, a nuclear nucleus that has been hanging on the cusp of the storm recently, wants to pass the exam.
The history of the nuclear genes made by this company did not start with gene detection . In the early days, it was mainly concentrated in the fields of decoration, retail, clothing design, real estate, etc. It was only in 2012 that it entered genetic testing, and nucleic acid testing was even worse.
Although "Zhang Shanshan" has attracted widespread attention from netizens, the key point behind Zhang Shanshan is. Zhang Shanshan appears in 36 companies as an executive, and all the positions she holds are supervisors. According to the survey, most of these 36 companies are directly and indirectly 100% of stake in by nuclear genes. It can be seen that Zhang Hezi and Baying and are the actual controllers of the nuclear Huaxi and nucleus genes. Now, relevant information shows that Zhang Hezi invested a total of 24 million yuan, holding 64.7% of the shares; Baying invested 4.5 million yuan, holding 12.13% of the shares, and the two held a total of nearly 77% of the shares. However, this is the result of the two preparing to reduce their holdings for listing.
Moreover, it is not recent that nuclear genes are going to be launched. Nuclear Gene has started preparing in 2016. In 2017, its founder Zhang Hezi promoted on the program that it already had 44 subsidiaries and 29 laboratories; after the COVID-19 testing began in 2020, its business has developed rapidly, and the main method is to develop investment agencies offline. In order to develop agents, Nuclear Gene even cooperates with online lending platforms and Internet installment platforms. It can be said that it is to recruit agents to make profits bigger. Among them, more than 100 agents made millions in the first half of 2020 alone. When launching the IPO listing plan, the advantage is that it has "46 subsidiaries and 31 laboratories" nationwide, and has "11 medical laboratory licenses and 20 judicial appraisal institute licenses", and is the "enterprise with the largest laboratory scale and licenses" in China.
Perhaps, nuclear genes are just to take advantage of the momentum of "Flying Pigs in the Wind". But unexpectedly, the "false positive" incident in Lanzhou gradually fermented, and not only the nuclear genes, but also the dream of major nucleic acid-related companies going public were almost shattered.
The epidemic has not ended yet, and people in many places across the country are still deeply troubled by the epidemic. They just claim that "wherever there is an epidemic, we will go wherever there is an epidemic." Upstream and downstream companies such as nucleic acid testing should not use the dividend to make money. In fact, the normal profit of and can be understood, but as an excellent wealth-making tool for corporate executives and original shareholders, this path really cannot be achieved if you want to go public. And behind the investigation, Lanzhou's "false positive" incident is just one of them, and companies under the name of nuclear genes have also been punished for repeated violations.
can be seen. These companies that want to take advantage of the Dongfeng listing are no wonder the torrent of public opinion. Because listing is equivalent to cashing out future profits, which is even more inconvenient for companies that make money in nucleic acid business.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-